Current and future use of dipyridamole in patients with COVID-19

• المؤلفون الرئيسيون: I. S. Burashnikova (مؤلف), V. M. Tsvetov (مؤلف), K. B. Mirzaev (مؤلف), D. A. Sychev (مؤلف)
• التنسيق: كتاب
• منشور في: Izdatelstvo OKI, 2020-10-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.